Swiss National Bank Acquires 2,900 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Swiss National Bank raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 8.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,100 shares of the company's stock after buying an additional 2,900 shares during the period. Swiss National Bank owned 0.14% of Krystal Biotech worth $7,117,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KRYS. EFG Asset Management North America Corp. grew its position in Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company's stock worth $2,308,000 after acquiring an additional 60 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after buying an additional 93 shares during the period. Nisa Investment Advisors LLC raised its holdings in Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company's stock valued at $173,000 after buying an additional 94 shares during the last quarter. Arizona State Retirement System raised its holdings in Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company's stock valued at $945,000 after buying an additional 108 shares during the last quarter. Finally, Fiera Capital Corp boosted its position in Krystal Biotech by 0.8% during the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company's stock worth $2,976,000 after buying an additional 130 shares during the period. Institutional investors own 86.29% of the company's stock.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.10% of the stock is owned by insiders.

Krystal Biotech Stock Up 1.0 %

NASDAQ:KRYS traded up $1.96 on Tuesday, hitting $196.52. The stock had a trading volume of 168,469 shares, compared to its average volume of 325,874. The company has a market cap of $5.65 billion, a PE ratio of 109.92 and a beta of 0.82. Krystal Biotech, Inc. has a 52 week low of $99.00 and a 52 week high of $219.34. The business's fifty day moving average is $179.55 and its 200 day moving average is $182.80.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business's revenue was up 879.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.67) earnings per share. Equities analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on KRYS. Chardan Capital raised their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a "buy" rating in a research note on Monday, August 5th. Cantor Fitzgerald reissued an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Evercore ISI upped their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th. Stifel Nicolaus raised their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. Finally, William Blair upgraded shares of Krystal Biotech to a "strong-buy" rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $202.29.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).